Compare Mesoblast Limited (MESO) vs Tesla, Inc. (TSLA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mesoblast Limited vs Tesla, Inc. — how do they compare? Mesoblast Limited trades at $14.29 (market cap $1.75B), while Tesla, Inc. trades at $382.7 (market cap $1.48T). The key difference: Tesla, Inc. is far larger — about 845.7× Mesoblast Limited's market cap, and Tesla, Inc. is trading nearer its 52-week high, Mesoblast Limited nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Mesoblast Limited for 15 Days and Tesla, Inc. for 88 Days on average.
| MESO | TSLA | |
|---|---|---|
Market Cap | $1.75B | $1.48T |
Volume | 239,027 | 28,215,427 |
Sector | Health | Consumer Cyclical |
52-Week High | $20.96 | $489.88 |
52-Week Low | $13.19 | $298.16 |
Typical Hold Time | 15 Days | 88 Days |
Enterprise Value | $1.83B | $1.45T |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MESO trades at $14.29, up 2.51% today, amid bearish technical signals but positive fundamental developments. The stock shows strong revenue growth with FY2026 reaching $120 million, though profitability remains negative. Recent FDA approval for Ryoncil's potency assay and completion of Phase 3 back pain trials provide catalysts. Technical indicators show oversold conditions with RSI at 22.4, while moving averages signal bearish momentum.
Investment outlook balances high growth potential against persistent losses. The expanding Ryoncil market share and pipeline progress offer upside, but negative margins and cash burn pose risks. Analyst consensus leans bullish with 45% buy ratings, yet the stock faces execution challenges in achieving profitability amid competitive pressures.
Tesla (TSLA) trades at $382.70, up 1.35% today, with a bullish technical signal from moving averages but mixed oscillators. The stock faces high valuation multiples (P/E 347.22, P/S 12.8) amid declining profitability, with net income margin falling to 3.67% in 2025. Recent news highlights regulatory approval for self-driving software in Europe and a potential cheaper EV launch, though Q2 2026 earnings missed expectations.
Tesla's outlook balances innovation in autonomy and energy against near-term execution risks and competitive pressures. The consensus price target of $441.36 suggests upside, but investors must weigh high valuation, margin compression, and volatile cash flows. Key catalysts include robotaxi progress and demand recovery, while risks involve execution delays and macroeconomic headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →About Tesla, Inc.
Tesla Inc. designs, manufactures, and sells high-performance electric vehicles and electric vehicle powertrain components. The Company owns its sales and service network and sells electric power train components to other automobile manufacturers. Tesla serves customers worldwide.
Read more on TSLA →
